Code Pharma, a biopharmaceutical company, has reported groundbreaking results from clinical trials of its innovative HIV treatment, Gammora. The treatment demonstrated highly favorable outcomes, including a significant reduction in viral load, with some patients reaching undetectable levels of the virus.
Gammora works by targeting and eliminating HIV-infected cells, offering a potential pathway to curing HIV rather than just managing it. The clinical results signal a major step forward in HIV treatment research, with Code Pharma now planning to advance to larger-scale trials to validate these findings.